Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS

Bone Marrow Transplantation

Volumn 23, Issue 10, 1999, Pages 997-1002

  Amigo, M L ^a   Del Canizo M C ^a   Rios, A ^a   Garcia, M A ^a   Caballero, M D ^a   Martin, A ^a   Bermejo, N ^a   Vilches, P ^a   San Miguel, J F ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Autologous transplantation; FAB criteria; Myelodysplastic features; Myelodysplastic syndromes

Indexed keywords

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL STRUCTURE; CYTOPENIA; EARLY DIAGNOSIS; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; THROMBOCYTOPOIESIS;

EID: 0033012372     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701757     Document Type: Article

References (30)

1. Stone RM. Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress. Blood 1994; 83: 3437-3440.
2. Miller J, Arthur DC, Litz CE et al. Myelodysplastic syndrome after autologous bone marrow transplantation. An additional late complication of curative cancer therapy. Blood 1994; 83: 3780-3786.
3. Traweek ST, Slovak ML, Nademanee AP et al. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow trasplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood 1994; 84: 957-963.
4. Rohatiner A. Myelodysplasia and acute myelogenous leukemia after myeloablative therapy with autologous stem-cell transplantation. J Clin Oncol 1994; 12: 2521-2523.
5. Darrington DL, Vose JM, Anderson J et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12: 2527-2534.
6. Stone RM, Neuberg D, Soiffer R et al. Myelodysplastic syndrome as a late complication following autologous bone marrow trasplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2535-2542.
7. Govindarajan R, Jagannath S, Flick JT et al. Preceding standard therapy is the likely cause of MDS after autologous autotransplants for multiple myeloma. Br J Haematol 1996; 95: 349-353.
8. Taylor PRA, Jackson GH, Lennard AL et al. Low incidence of myelodysplastic syndrome following transplantation using autologous non-cryopreserved bone marrow. Leukemia 1997; 11: 1650-1653.
9. Pedersen-Bjergaard J, Pedersen M, Myhre J, Geisler C. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Leukemia 1997; 11: 1654-1660.
10. Deeg HJ, Socié G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998; 91: 1833-1844.
11. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
12. Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myelodysplastic syndrome: a clinical and morphological study of 65 cases. Blood 1985; 65: 1364-1372.
13. Verwilghen RL, Boogaerts MA. The myelodysplastic syndromes. Blood Rev 1987; 1: 34-43.
14. Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992; 19: 47-84.
15. Wilson CS, Traweek T, Slovak ML et al. Myelodysplastic syndrome occurring after autologous bone marrow transplantation for lymphoma. Am J Clin Pathol 1997; 108: 369-377.
16. García S, Sanz MA, Amigo V et al. Prognostic factors in chronic myelodysplastic syndromes: a multivariate analysis in 107 cases. Am J Hematol 1988; 27: 163-167.
17. Sanz GF, Sanz MA, Vallespí T et al. Two regression models and scoring system for predicting survival and planning treatment in myelodysplastic syndromes. A multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395-408.
18. Marmont AM. Morphological bone marrow studies after allogenic marrow transplantation in man for severe aplastic anaemia and acute leukaemia. Nouv Rev Fr Hematol 1979; 21: 133-148.
19. Rozman C, Feliu E, Grañena A et al. Transient dyserythropoiesis in repopulated human bone marrow following transplantation. An ultrastructural study. Br J Haematol 1982; 50: 63-73.
20. Masat T, Feliu E, Villamor N et al. Immunophenotypic and ultrastructural study in peripheral blood neutrophil granulocytes following bone marrow transplantation. Br J Haematol 1997; 98: 299-307.
21. Soligo DA, Lambertenghi Deliliers G, Servida F et al. Haematopoietic abnormalities after autologous stem cell transplantation in lymphoma patients. Bone Marrow Transplant 1998; 21: 15-22.
22. Bacigalupo A, Piaggio G, Podesta M et al. Influence of marrow CFU-GM content on engraftment and survival after allogenic bone marrow. Bone Marrow Transplant 1995; 15: 221-226.
23. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplantation for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
24. Michelson JD, Gornet M, Codd M et al. Bone marrow morphology after bone marrow transplantation for Hodgkin's and non-Hodglin's lymphoma. Exp Hematol 1993; 21: 475-482.
25. Verhoef GEG, Pittaluga S, De Wolf-Peeters C, Boogaerts MA. FAB classification of myelodysplastic syndromes: merits and controversies. Ann Hematol 1995; 71: 3-11.
26. Chao NJ, Nademanee AP, Long GD et al. Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease. J Clin Oncol 1991; 9: 1575-1579.
27. Gale RE, Bunch C, Moir DJ et al. Demonstration of developing myelodysplasia/acute myeloid leukemia in haematologically normal patients after high-dose chemotherapy and autologous bone marrow transplantation using X-chromosome inactivation patterns. Br J Haematol 1996; 93: 53-58.
28. Legare RD, Gribben JG, Maragh M et al. Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma. Am J Hematol 1997; 56: 45-51.
29. Abruzzese E, Radford JE, Miller JS et al. Detection of abnormal pre-transplant clones in progenitor cells of patients who developed myelodysplasia after myeloablative therapy. Blood 1997; 90 (Suppl. 1): (Abstr. 2625).
30. Amigo ML, del Cañizo MC, Hernández JM et al. Clonal myelodysplastic cells present in apheresis product previous to transplantation. Leukemia 1998; 12: 1497-1499.